DOCSLIB.ORG

Effectiveness of Tirofiban, Eptifibatide, and Abciximab in Minimizing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effectiveness of Tirofiban, Eptifibatide, and Abciximab in Minimizing Effectiveness of Tirofiban, Eptifibatide, and Abciximab in Minimizing Myocardial Necrosis During Percutaneous Coronary Intervention (TEAM Pilot Study)* Annapoorna S. Kini, MD, MRCP, Merwin Richard, MD, Javed Suleman, MD, Nohelia Perez, Paul Lee, MD, Edward A. Fisher, MD, Mazullah Kamran, MD, Jonathan D. Marmur, MD, and Samin K. Sharma, MD ver the last decade, several randomized trials of Blinded drug boluses were provided in a syringe with Oplatelet glycoprotein (GP) IIb/IIIa inhibitors dur- filter. The study protocol is shown in Figure 1. All ing percutaneous coronary intervention (PCI) have patients received weight-adjusted low-dose heparin been shown to reduce ischemic complications, death, (50 U/kg), aspirin 325 mg, and plavix 300 mg at the and nonfatal myocardial infarction, and release of start of PCI. Activated clotting time was targeted to be periprocedural creatine kinase-MB (CK-MB).1–5 Ben- between 200 and 250 seconds. Baseline platelet reac- eficial effects of GP IIb/IIIa inhibitors during PCI are tivity was measured as platelet aggregation units using primarily due to optimal platelet inhibition (PI) as the Ultegra device (Accumetrics, San Diego, Califor- reflected by a decrease in platelet-mediated distal mi- nia). Randomized GP inhibitor was administered in crothrombolism.1–6 The 3 GP inhibitors have distinct recommended bolus doses followed by an infusion binding characteristics, different specificities for drip. At 10 minutes, if PI was Յ90%, a second half platelet IIb/IIIa receptors, and different costs. In ad- bolus of the study drug was administered and PCI was diton, there has been no head-to-head comparison started. In these cases, PI was recalculated 10 minutes between these agents with regard to levels of PI and after a second half-bolus, but no additional bolus short-term clinical outcomes. The present pilot trial doses of GP inhibitor were administered due to safety was performed to test the hypothesis that high-risk concerns, even if PI was Յ90%. Abciximab was given PCI performed in the setting of Ͼ90% PI, regardless as an 0.25 mg/kg bolus, followed by an infusion of of the type of GP inhibitor used, will result in similar 0.125 ␮g/kg/min (maximum of 10 ␮g/min) for 12 periprocedural enzyme release and 30-day major ad- hours. Tirofiban was given as 10 ␮g/kg bolus, fol- verse cardiac events (MACE). lowed by an infusion of 0.15 ␮g/kg/min for 12 hours. Eptifibatide was given as 180 ␮g/kg bolus, followed ••• by infusion of 2 ␮g/kg/min for 12 hours. All patients In all, 183 patients with high-risk clinical features had CK-MB and troponin I measured at baseline, 6 to of post-myocardial infarction, pain at rest, and/or 8 and 12 to 24 hours after the procedure. Aspirin 81 to complex angiographic lesions (American College of 325 mg and clopidogrel 75 mg (if the stent was Cardiology/American Heart Association type C, deployed) were continued for 30 days. thrombotic, ulcerated, bifurcation, or heavily calci- Platelet aggregation measurement was performed fied) were included in the study from February 8, 2000 using the Ultegra Rapid Platelet Function Assay de- to July 20, 2000. Patients at increased risk of bleeding, vice. Details of this point-of-care platelet function test with myocardial infarction in Ͻ72 hours, vein graft have been described previously.7 The anticoagulant PCI, chronic total occlusion, elevated CK-MB values Phe-Pro-Arg chloromethyl ketone was used in all at baseline, prior abciximab use within 1 year, or cases. All specimens were maintained at room tem- eptifibatide/tirofiban infusion within 24 hours before perature and analyzed within 30 minutes. Platelet ag- PCI were excluded. The institutional review board gregation units were measured at baseline, at 10 min- approved the study and all patients signed the in- utes, at 10 minutes after the second bolus of GP formed consent documents. Patients who met the eli- inhibitor, and at 4 to 6 and 13 to 20 hours after the gibility criteria were randomly assigned to receive the procedure. study drug by the pharmacist who was not blinded. The primary end points of the study were the incidence of periprocedural cardiac enzyme elevation From the Cardiac Catheterization Laboratory of the Zena & Michael A. (CK-MB and troponin I) and 30-day MACE (death, Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, myocardial infarction with CK-MB Ͼ3 times the up- New York. This report was supported by unrestricted grants from per limit of normal, and urgent revascularization). Merck Inc., West Point, Pennsylvania; and COR Therapeutics Inc., South San Francisco, California. Dr. Sharma’s address is: Mount Sinai Secondary end points were degree of PI at various Hospital, Box 1030, One Gustave Levy Place, New York, New York time points, need for additional bolus of GP inhibitor 10029-6574. E-mail: [email protected]. Manuscript agent, incidence of major and minor bleeding, and received February 4, 2002; revised manuscript received and ac- cost analysis. cepted April 30, 2002. Statistical analysis was performed using SAS/JMP *There is no conflict of interest either real or perceived of any author in (Cary, North Carolina) and SPSS 10.0 (Chicago, Illi- the publication of this manuscript. nois) systems. Results are presented as mean Ϯ SD, 526 ©2002 by Excerpta Medica, Inc. All rights reserved. 0002-9149/02/$–see front matter The American Journal of Cardiology Vol. 90 September 1, 2002 PII S0002-9149(02)02528-6 logistic regression was used to iden- tify predictors for dichotomous out- come and are presented as odds ra- tios and 95% confidence intervals. A p value of Ͻ0.05 was considered statistically significant. A total of 183 patients (mean age 65 Ϯ 11 years) were enrolled in this pilot study; 3 patients were ex- cluded from analysis because of protocol deviation (1 vein graft in- tervention, 2 incomplete platelet ag- gregation measurements). Of these, 56 patients received tirofiban, 61 received eptifibatide, and 63 re- ceived abciximab. Baseline clinical characteristics among the 3 groups were not different; 35% were women. In the entire cohort, 88% had sys- temic hypertension, 35% diabetes platelet mellitus, 47% angina at rest, 15% ؍ activated clotting time; PAU ؍ FIGURE 1. Protocol of TEAM pilot trial. ACT aggregation units. post-myocardial infarction, 25% prior myocardial infarction, 53 Ϯ TABLE 1 Angiographic and Procedural Characteristics in TEAM Trial 8% mean left ventricular ejection fraction, and 18% multivessel inter- Tirofiban Eptifibatide Abciximab All vention. Angiographic and proce- Variables (n ϭ 56) (n ϭ 61) (n ϭ 63) (n ϭ 180) dural characteristics are listed in Ta- ACC/AHA type B2 31 (55%) 32 (52%) 33 (52%) 96 (53.3%) ble 1; in-hospital complications are ACC/AHA type C 25 (45%) 29 (48%) 30 (48%) 84 (46.7%) listed in Table 2. Characteristics Calcification 27 (48.2%) 35 (57.3%) 36 (57.1%) 98 (54.4%) Thrombus 13 (23.2%) 16 (26.2%) 15 (23.8%) 44 (24.4%) were similar among the 3 groups. Bifurcation 8 (14.2%) 11 (18.0%) 12 (19.0%) 31 (17.2%) The overall incidence of CK-MB Ostial 5 (8.9%) 7 (11.5%) 6 (9.5%) 18 (10%) elevation (Figure 2) was 15% and of Lesion length (mm) 12.5 14.2 14.2 13.6 Ϯ 5.3 troponin I elevation 26.7%, with no Reference vessel size (mm) 3.03 3.11 2.91 3.01 Ϯ 0.46 Before MLD (mm) 0.67 0.87 0.81 0.78 Ϯ 0.21 significant differences among the 3 Before Stenosis (%) 78 73 72 74 Ϯ 8 groups. A total of 8 patients (4.4%) Intervention experienced 30-day MACE: 2 myo- Stent alone 26 (46.4%) 28 (46.6%) 27 (42.3%) 81 (45%) cardial infarctions and 1 urgent revas- ϩ Rotablator stent 22 (39.3%) 23 (37.7%) 25 (39.7%) 70 (38.9%) cularization in the tirofiban group AngioJet ϩ stent 3 (5.3%) 5 (8.2%) 4 (6.3%) 12 (6.7%) Rotablator only 2 (3.6%) 4 (6.6%) 4 (6.3%) 10 (5.5%) (5.4%), 1 myocardial infarction and 1 Balloon only 1 (1.8%) 1 (1.6%) 2 (3.2%) 4 (2.2%) death in the eptifibatide group (3.3%), After MLD (mm) 2.77 2.79 2.87 2.81 Ϯ 0.31 and 1 myocardial infarction, 1 urgent After Stenosis (%) 21 17 16 18 Ϯ 6 revascularization, and 1 death in the Angiographic success 54 (96.4%) 59 (96.7%) 61 (96.8%) 174 (96.7%) ϭ Procedural success 55 (98.2%) 60 (98.4%) 62 (98.4%) 177 (98.3%) abciximab group (4.8%) (p NS). Only 52% of the patients achieved ACC/AHA ϭ American College of Cardiology/American Heart Association; MLD ϭ minimum lumen aPIofϾ90% 10 minutes after the first diameter. bolus; the remaining 48% received the second half-bolus. The final PI before PCI in the entire cohort was 93 Ϯ 2%. median (interquartile range), or number (percent) as The need for the second bolus was 59% in those taking appropriate. Baseline characteristics among treatment tirofiban, 33% in those taking eptifibatide, and 51% in groups were compared using analysis of variance the abciximab group (p ϭ 0.002 by ANOVA among the (ANOVA) for continuous variables and Pearson’s chi- 3 groups). There were no significant differences in PI square test or Fisher’s exact test for nominal variables. values at 4 to 6 and 13 to 20 hours among the 3 groups. Because CK-MB and troponin I failed the Shapiro- The peak activated clotting time was 248, 256, and 261 Wilk test for normality, a multiple group comparison seconds in the tirofiban, eptifibatide, and abciximab of these continuous variables was performed using groups, respectively (p ϭ NS).
Load more

Recommended publications
  • Safety of Tirofiban for Patients with Acute Ischemic Stroke in Routine Clinical Practice
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 169-174, 2015 Safety of tirofiban for patients with acute ischemic stroke in routine clinical practice YUAN-QUN ZHU1, YAN-JUN ZHANG2, HAI-LIN RUAN3, QING LIU2, QIN ZHAN2 and QIONG LI2 1Department of Neurology, Liuzhou Worker's Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005; 2Department of Geriatrics, People's Hospital of Zhengzhou, Zhengzhou, Henan 450003; 3Department of Emergency, Liuzhou Worker's Hospital, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, P.R. China Received April 11, 2014; Accepted December 8, 2014 DOI: 10.3892/etm.2015.2495 Abstract. The aim of the present study was to investigate the Introduction safety of tirofiban alone and in combination with various treat- ments in acute ischemic stroke (AIS). A total of 120 patients Acute ischemic stroke (AIS) is a common cause of morbidity with AIS were included in the study, and these patients were and mortality worldwide. Thrombolysis with recombinant divided into three treatment groups: Group A (tirofiban alone, tissue plasminogen activator (rtPA) is the only proven beneficial n=68), group B (tirofiban plus thrombolytic therapy, n=26), therapy in AIS, and this is received by <2% of patients (1). The and group C (tirofiban as a ‘bridging therapy’, n=26). Risk inaccessibility of this treatment to the majority of patients is due factors, stroke severity, initial imaging, treatment regimens, to a number of factors: A lack of adequate transport facilities complications and long‑term outcomes were analyzed. In and infrastructure, including facilities for thrombolysis in most total, eight patients (6.7%) [six patients (23.1%) in group B centers; the high cost of tPA; and a lack of awareness among and two patients (7.7%) in group C] had hemorrhage during the public and doctors (2).
    [Show full text]
  • Summary of the Product Characteristics
    Tirofiban hydrochloride Hikma Pharma GmbH SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT <TIROFIBAN>® *50 micrograms/mL Solution for infusion <TIROFIBAN>® *250 micrograms/mL Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION <TIROFIBAN> Solution: 1 ml of solution for infusion contains 56 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms Tirofiban. This medicinal product contains 31 mmol (or 715 mg) sodium per bag (250 ml). To be taken into consideration by patients on a controlled sodium diet. <TIROFIBAN> Concentrate: 1 ml of concentrate for solution for infusion contains 281 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms Tirofiban. 50 ml of concentrate for solution for infusion contains 14,05 mg of tirofiban hydrochloride monohydrate which is equivalent to 12,5 mg Tirofiban. This medicinal product contains less than 1 mmol sodium (23 mg) per vial (50 ml), i.e. essentially ‘sodium- free’. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM <TIROFIBAN> Solution: Solution for Infusion (250 ml bag) A clear, colourless solution. <TIROFIBAN> Concentrate: Concentrate for solution for infusion. A clear, colourless concentrated solution. * in the following document the abbreviated terms detailed below are used. • <TIROFIBAN> means <TIROFIBAN> Solution for Infusion or <TIROFIBAN> Concentrate for Solution for Infusion. • <TIROFIBAN> Solution will be used when referring to <TIROFIBAN> Solution for Infusion
    [Show full text]
  • Eptifibatide Is Noninferior to Abciximab: Implications for Clinical Practice
    RESEARCH HIGHLIGHTS ANTIPLATELET THERAPY Eptifibatide is noninferior to abciximab: implications for clinical practice he glycoprotein IIb/IIIa (GPIIb/ randomized, open, parallel-group January 2004 and December 2007, IIIa) inhibitors eptifibatide and comparison of eptifibatide and abciximab and eptifibatide was used in 2,355 Tabciximab have comparable efficacy in 427 patients presenting within 12 h such procedures over this time frame. and safety in patients with ST-segment of STEMI onset and who underwent During the 1-year follow-up period, elevation myocardial infarction (STEMI) primary PCI. Enrolled patients were from no significant difference was reported undergoing primary percutaneous 22 centers in France and Germany. The for the incidence of death (8.0% and coronary intervention (PCI). These two study drugs were administered in 7.6%), myocardial infarction (9.0% and findings, from a randomized trial and a combination with background therapy 8.4%), or bleeding (2.7% and 3.2%) registry study, are reported in two papers comprising clopidogrel, aspirin, and between abciximab and eptifibatide, published in the Journal of the American heparin or enoxaparin. This study used respectively. Multivariable analysis College of Cardiology (JACC). the surrogate primary end point of showed that eptifibatide was noninferior Platelet aggregation and thrombus complete electrocardiographic ST-segment to abciximab for the prevention of death formation can be inhibited by blocking resolution (STR) 60 min after completion or myocardial infarction (odds ratio 0.94, the GPIIb/IIIa receptor on the platelet of PCI. 95% CI 0.82–1.09). membrane, thereby preventing the binding In the intention-to-treat analysis, These findings “fuel an already much of fibrinogen.
    [Show full text]
  • The Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes Marc Cohen, MD, FACC Newark, New Jersey
    CORE Metadata, citation and similar papers at core.ac.uk Provided by ElsevierJournal - ofPublisher the American Connector College of Cardiology Vol. 41, No. 4 Suppl S © 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/S0735-1097(02)02901-7 The Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes Marc Cohen, MD, FACC Newark, New Jersey A substantial number of clinical studies have consistently demonstrated that low-molecular- weight heparin (LMWH) compounds are effective and safe alternative anticoagulants to unfractionated heparins (UFHs). They have been found to improve clinical outcomes in acute coronary syndromes and to provide a more predictable therapeutic response, longer and more stable anticoagulation, and a lower incidence of UFH-induced thrombocytopenia. Of the several LMWH agents that have been studied in large clinical trials, including enoxaparin, dalteparin, and nadroparin, not all have shown better efficacy than UFH. Enoxaparin is the only LMWH compound to have demonstrated sustained clinical and economic benefits in comparison with UFH in the management of unstable angina/ non–ST-segment elevation myocardial infarction (NSTEMI). Also, LMWH appears to be a reliable and effective antithrombotic treatment as adjunctive therapy in patients undergoing percutaneous coronary intervention. Clinical trials with enoxaparin indicate that LMWH is effective and safe in this indication, with or without the addition of a glycoprotein IIb/IIIa inhibitor. The efficacy demonstrated by enoxaparin in improving clinical outcomes in unstable angina/NSTEMI patients has led to investigations of its role in the management of ST-segment elevation myocardial infarction.
    [Show full text]
  • Code ATC B01 : Antithrombotiques
    Département fédéral de l'économie, de la formation et de la recherche DEFR Office fédéral pour l'approvisionnement économique du pays OFAE domaine produits thérapeutiques 18 décembre 2020 Code ATC B01 : antithrombotiques Rapport sur les risques de de sous-approvisionne- ment en antithrombotiques (code ATC B01) : première évaluation 2019 Rapport sur les risques de sous-approvisionnement en antithrombotiques Table des matières 1. Résumé ........................................................................................................................................... 4 2. Objectif ............................................................................................................................................. 5 3. Analyse ............................................................................................................................................ 5 3.1. Procédure ................................................................................................................................ 5 3.2. Bases moléculaires de l’hémostase ........................................................................................ 6 3.3. Thrombose ............................................................................................................................... 6 4. Prophylaxie et traitement des thromboses et des thromboembolies (antagonistes de la vitamine K et anticoagulants oraux directs, code ATC B01AA) ................................................................................ 7 4.1 Utilisation et
    [Show full text]
  • Deliverable 5.A Interim Report on the Study Results APPENDIX 2
    Deliverable 5.a Interim report on the study results APPENDIX 2: Algorithms used to identify study variables for service contract EMA/2011/38/CN ‐ PIOGLITAZONE November 28th 2012 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) APPENDIX 2. ALGORITHMS USED TO IDENTIFY STUDY VARIABLES Algorithms for AU Database DISEASE/CONDITION ICD-8 CODE (1977-1993) ICD-10 CODE (1994-) Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9 Cancer of bladder 188 C67 Haematuria N/A R31 Haematuria, unspecified B18, K70.0–K70.3, K70.9, K71, K73, Mild hepatic impairment 571, 573.01, 573.04 K74, K76.0 Moderate to severe hepatic 070.00, 070.02, 070.04, 070.06, B15.0, B16.0, B16.2, B19.0, K70.4, impairment 070.08, 573.00, 456.00–456.09 K72, K76.6, I85 Acute myocardial infarction 410 I21-I23 Acute coronary syndrome 410, 413 I20-I24 Ischemic heart disease 410-414 I20-I25 427.09, 427.10, 427.11, 427.19, Congestive heart failure I50, I11.0, I13.0,I13.2 428.99, 782.49; Acute renal failure N/A N17 Diabetic coma N/A E10.0, E11.0, E12.0,E13.0, E14.0 Diabetic acidosis N/A E10.1, E11.1, E12.1,E13.1, E14.1 F10.1-F10.9, G31.2, G62.1, G72.1, Alcoholism 291, 303, 577.10, 571.09, 571.10 I42.6, K29.2, K86.0, Z72.1 Obesity 277.99 E65-E66 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) Algorithms for defining acute events in Denmark, ICD-10 code Event ICD-10 code I21.x, I23.x http://apps.who.int/classifications/icd10/browse/2010/en#/I21
    [Show full text]
  • GP Iib/Iiia Adult Cardiology Treatment Dosing and Monitoring Guidelines
    GP IIb/IIIa Inhibitor Adult Cardiology Treatment Dosing and Monitoring Guidelines During times of eptifibatide shortage, the following guidance is available for tirofiban usei Eptifibatide (Integrilin®) Tirofiban (Aggrastat®) Dosing Loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) Loading dose: 25 mcg/kg IV over 5 minutes ii ACS Maintenance infusion: 2 mcg/kg/minute (max: 15 mg/hr) up to 72 hours Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18 (until discharge or CABG surgery) hours st 1 Loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) Loading dose: 25 mcg/kg IV over 5 minutes ii PCI Maintenance infusion: 2 mcg/kg/minute (max: 7.5 mg/hr) continued for Maintenance infusion: 0.15 mcg/kg/minute continued for up to 18 up to 18 to 24 hours hours 2nd loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) should be administered 10 minutes after the first bolus Dose Adjustment For CrCl ≤ 50 mL/minute: For CrCl ≤ 60 mL/minute: 1st loading dose: 180 mcg/kg IV bolus (max: 22.6 mg) Loading dose: 25 mcg/kg IV over 5 minutes Maintenance infusion: 2 mcg/kg/minute (max 7.5 mg/hr) Maintenance infusion: 0.075 mcg/kg/minute continued for up to 18 2nd loading dose (if PCI): 180 mcg/kg IV bolus (max: 22.6 mg) should be hours administered 10 minutes after the first bolus For end-stage renal disease: CONTRAINDICATED Contraindications − Severe hypersensitivity reaction to eptifibatide − Severe hypersensitivity reaction to tirofiban − History of bleeding diathesis or evidence of active abnormal bleeding − A history of thrombocytopenia following prior
    [Show full text]
  • Summary of the Product Characteristics
    Tirofiban hydrochloride Welding GmbH & Co.KG 1.3 Product Information SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT <TIROFIBAN>® *50 micrograms/mL Solution for infusion <TIROFIBAN>® *250 micrograms/mL Concentrate for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION <TIROFIBAN> Solution: 1 ml of solution for infusion contains 56 micrograms of Tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms Tirofiban. This medicinal product contains 31 mmol (or 715 mg) sodium per bag (250 ml). To be taken into consideration by patients on a controlled sodium diet. <TIROFIBAN> Concentrate: 1 ml of concentrate for solution for infusion contains 281 micrograms of Tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms Tirofiban. 50 ml of concentrate for solution for infusion contains 70.2514,05 mg of Tirofiban hydrochloride monohydrate which is equivalent to 62.512,5 mg Tirofiban. This medicinal product contains less than 1 mmol sodium (23 mg) per vial (50 ml), i.e. essentially ‘sodium- free’. For excipients, see section 6.1. 3 PHARMACEUTICAL FORM <TIROFIBAN> Solution: Solution for Infusion (250 ml bag) A clear, colourless solution. <TIROFIBAN> Concentrate: Concentrate for solution for infusion. A clear, colourless concentrated solution. * in the following document the abbreviated terms detailed below are used. • <TIROFIBAN> means <TIROFIBAN> Solution for Infusion or <TIROFIBAN> Concentrate for Solution for Infusion. • <TIROFIBAN> Solution will be used when referring to <TIROFIBAN>
    [Show full text]
  • NDA 20-718/S-025 Page 2 of 18 Integrilin (Eptifibatide)
    NDA 20-718/S-025 Page 2 of 18 Integrilin (eptifibatide) Injection For Intravenous Administration DESCRIPTION Eptifibatide is a cyclic heptapeptide containing six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. An interchain disulfide bridge is formed between the cysteine amide and the mercaptopropionyl moieties. Chemically it is N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L--aspartyl-L-tryptophyl-L-prolyl-L- cysteinamide,cyclic (1→6)-disulfide. Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. The eptifibatide peptide is produced by solution-phase peptide synthesis, and is purified by preparative reverse-phase liquid chromatography and lyophilized. The structural formula is: Integrilin (eptifibatide) Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each 10-mL vial contains 2 mg/mL of eptifibatide and each 100-mL vial contains either 0.75 mg/mL of eptifibatide or 2 mg/mL of eptifibatide. Each vial of either size also contains 5.25 mg/mL citric acid and sodium hydroxide to adjust the pH to 5.35. CLINICAL PHARMACOLOGY Mechanism of Action. Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion; this is thought to result from dissociation of eptifibatide from the platelet. Pharmacodynamics. Infusion of eptifibatide into baboons caused a dose-dependent inhibition of ex vivo platelet aggregation, with complete inhibition of aggregation achieved at infusion rates greater than 5.0 µg/kg/min.
    [Show full text]
  • Ticagrelor Versus Clopidogrel and Eptifibatide Bolus in Patients with Stable Or Unstable Angina Undergoing Coronary Intervention: a Randomized Pharmacodynamic Study
    Ticagrelor versus Clopidogrel and Eptifibatide Bolus in Patients with Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study Study Protocol & Statistical Analysis Plan NCT02925923 December 17, 2019 Massoud A. Leesar, M.D., Principal Investigator University of Alabama at Birmingham Birmingham, AL 35294 Ticagrelor versus Clopidogrel and Eptifibatide Bolus in Patients with Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study Moazez Marian, PhD, Olseun Alli, MD, Firas Al soliman, MD; Mark Sasse, MD, Arka Chatterjee, MD, Himanshu Aggarwal, MD, Andrew Kurtlinsky, MD Massoud Leesar, MD Division of Cardiology, UAB Center for Thrombosis Research, University of Alabama, Birmingham Address for Correspondence: Massoud A. Leesar, MD Division of Cardiology University of Alabama-Birmingham Birmingham, AL, 35294 Telephone: (205) 975-0816 E-mail: [email protected] 2 In the Ad Hoc percutaneous coronary intervention (PCI) study (Presented at the SCAI meeting, 2015), 100 patients with troponin-negative acute coronary syndrome were randomized to receive ticagrelor (180mg loading dose [LD] and 90mg after 12hr) or clopidogrel (600mg LD and 75 mg TM after 12 h) with aspirin 75–100mg daily. P2Y12 reactivity unit [PRU] using VerifyNow assay was measured pre-LD, and at 0.5, 2 and 8 h post LD. At 2 h, PRU was lower with ticagrelor vs. clopidogrel (98.4 ± 95.4 vs. 257.5 ± 74.5, respectively; p<0.001). PRU diverged as early as 0.5 h post ticagrelor LD and there was a significant reduction in the PRU level with ticagrelor. The rate of high on-treatment PRU level was significantly reduced with ticagrelor compared with clopidogrel at 2 h (13.3% vs.
    [Show full text]
  • AHS Provincial High-Alert Medication List
    Provincial High-alert Medication List Classes/Categories of Medications Specific Medications adrenergic agonists: IV (e.g., epiNEPHrine, ePHEDrine, isoproterenol, magnesium sulfate injection PHENYLephrine, norepinephrine, doBUTamine, doPAMine, salbutamol) methotrexate: oral for non-oncologic adrenergic antagonists: IV (e.g., propranolol, metoPROLOL, labetalol, use esmolol) nitroprusside sodium for injection anesthetic agents: general, inhaled and IV (e.g., propofol, ketamine, sevoflurane, isoflurane, desflurane, etomidate) opium tincture antiarrhythmics: IV (e.g., lidocaine, amiodarone, procainamide, oxytocin: IV adenosine, bretylium, ibutilide) potassium chloride for injection: antithrombotic agents: concentrate anticoagulants (e.g., warfarin, acenocoumarol, tinzaparin, potassium phosphates injection enoxaparin, dalteparin, danaparoid, unfractionated heparin, sodium citrate) promethazine: IV factor Xa inhibitors (e.g., fondaparinux, rivaroxaban) vasopressin: IV or intraosseous direct thrombin inhibitors (e.g., apixaban, argatroban, bivalirudin, dabigatran) thrombolytics (e.g., alteplase, tenecteplase) glycoprotein IIb/IIIa inhibitors (e.g.,eptifibitide, tirofiban, abciximab) cardioplegic solutions chemotherapeutic agents: parenteral and oral dextrose: 20% or greater (hypertonic) dialysis solutions: peritoneal and hemodialysis The following medications are also epidural or intrathecal medications associated with higher risk and must inotropic medications: IV (e.g., digoxin, milrinone) comply with the segregated storage and labelling
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]